CN112546135A - 一种解酒、醒酒、护肝的中药组合物及其应用 - Google Patents
一种解酒、醒酒、护肝的中药组合物及其应用 Download PDFInfo
- Publication number
- CN112546135A CN112546135A CN202011509077.3A CN202011509077A CN112546135A CN 112546135 A CN112546135 A CN 112546135A CN 202011509077 A CN202011509077 A CN 202011509077A CN 112546135 A CN112546135 A CN 112546135A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- medicine composition
- sobering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 63
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims abstract description 30
- 210000004185 liver Anatomy 0.000 title claims abstract description 30
- 230000000694 effects Effects 0.000 title claims abstract description 15
- 241000132012 Atractylodes Species 0.000 claims abstract description 24
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 24
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 24
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 22
- 229940079593 drug Drugs 0.000 claims abstract description 21
- 244000111489 Gardenia augusta Species 0.000 claims abstract description 19
- 208000007848 Alcoholism Diseases 0.000 claims abstract description 18
- 241000037740 Coptis chinensis Species 0.000 claims abstract description 18
- 235000018958 Gardenia augusta Nutrition 0.000 claims abstract description 18
- 240000004534 Scutellaria baicalensis Species 0.000 claims abstract description 18
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims abstract description 18
- 241000222684 Grifola Species 0.000 claims abstract description 17
- 201000007930 alcohol dependence Diseases 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 241000972672 Phellodendron Species 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 206010019133 Hangover Diseases 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 241000222640 Polyporus Species 0.000 claims description 5
- 238000009835 boiling Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 241000972673 Phellodendron amurense Species 0.000 claims description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 3
- 230000035987 intoxication Effects 0.000 claims description 3
- 231100000566 intoxication Toxicity 0.000 claims description 3
- 238000002386 leaching Methods 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 230000001376 precipitating effect Effects 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 230000036772 blood pressure Effects 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims 1
- 230000035622 drinking Effects 0.000 abstract description 14
- 210000002700 urine Anatomy 0.000 abstract description 5
- 230000004060 metabolic process Effects 0.000 abstract description 4
- 241000721047 Danaus plexippus Species 0.000 abstract description 3
- 230000029142 excretion Effects 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 2
- 206010036067 polydipsia Diseases 0.000 abstract 1
- 210000000952 spleen Anatomy 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
- 230000002618 waking effect Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 19
- 230000000052 comparative effect Effects 0.000 description 13
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 10
- 239000013641 positive control Substances 0.000 description 8
- 206010015150 Erythema Diseases 0.000 description 7
- 238000010926 purge Methods 0.000 description 6
- 241000218691 Cupressaceae Species 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 206010067125 Liver injury Diseases 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 4
- 210000000232 gallbladder Anatomy 0.000 description 4
- 231100000753 hepatic injury Toxicity 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010000060 Abdominal distension Diseases 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 3
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000036578 sleeping time Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010013954 Dysphoria Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 244000171085 Polyporus umbellatus Species 0.000 description 2
- 235000004837 Polyporus umbellatus Nutrition 0.000 description 2
- 244000197580 Poria cocos Species 0.000 description 2
- 235000008599 Poria cocos Nutrition 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 231100000570 acute poisoning Toxicity 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 231100000739 chronic poisoning Toxicity 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004622 sleep time Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 229940123257 Opioid receptor antagonist Drugs 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 235000001188 Peltandra virginica Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002075 anti-alcohol Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000010015 huanglian Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000003401 opiate antagonist Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000028527 righting reflex Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 201000006134 tongue cancer Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种解酒、醒酒、护肝的中药组合物及其应用,所述中药组合物由以下重量份的原料药组成:黄芩6‑18份、黄连4‑15份、黄柏4‑15份、山栀子4‑15份、白茯苓9‑15份、猪苓9‑15份、泽泻12‑18份、白术9‑15份,桂枝6‑12份。本发明还包括所述中药组合物在制备解酒、醒酒、护肝的药物中的应用。其优点表现在:本发明的中药组合物配伍理论符合中医“君臣佐使”的理论,配伍有序,诸药合用具有解酒毒,除烦渴,醒脾胃,化湿浊的功效。临床使用情况表明:醉酒患者服用该组方后可减缓喝酒后的红脸及快速心跳,加速酒精在体内代谢,通过小便排泄,达到醒酒的效果。比单用其中几味药材疗效好,总有效率高达100%。
Description
技术领域
本发明涉及中药技术领域,具体地说,是一种解酒、醒酒、护肝的中药组合物及其应用。
背景技术
酒精中毒俗称醉酒,是指患者一次饮用大量酒精后发生的机体机能异常状态,其对神经系统和肝脏伤害最严重。医学上将其分为急性中毒和慢性中毒两种,前者可在短时间内给患者带来较大伤害,甚至可以直接或间接导致死亡。后者给患者带来的是累积性伤害,如酒精依赖、精神障碍、酒精性肝硬化及诱发某些癌症(口腔癌、舌癌、食管癌、肝癌)等。
人体代谢酒精应该分为三种代谢方式:
第一种:饮酒时大量出汗,频繁小便,酒量极高,这就是以上所述的一种,这种人极少醉酒,因其体内还存有二个酶即乙醇脱氢酶和乙醛脱氢酶,将酒精迅速转化成乙酸进入TCA循环而发热,大量发热而出汗,频繁的小便,将二氧化碳和水排出体外。二个酶活性越高越能喝,但这类人已不多。
第二种:酒量比较厉害,越喝脸越白,到一个点突然不行,烂醉如泥。这是二个酶均没有的一种,其以体液来稀释保存乙醇,靠肝脏里的P450(P450是特异性比较低的一群氧化酶)将乙醇慢慢氧化,最后氧化成二氧化碳和水排出体外。这种人,体液越多稀释保存乙醇就越多,越能喝,因乙醛刺激毛细血管扩张及刺激人体中枢神经系统是乙醇的十倍以上,这种人乙醇氧化慢,乙醇对人体刺激也慢,所以给人很能喝酒的感觉。这种人醉酒慢,醒酒也慢,特别容易伤肝脏。也是需要醒酒解酒的主要对象。
第三种:酒量普通,一杯喝下就脸红,很多人以为酒精导致,其实不然,而是乙醛。这种人只有乙醇脱氢酶,能迅速将乙醇代谢为乙醛,由于乙醛不能马上代谢,在体内迅速累积刺激皮肤毛细血管扩张,形成脸红,(乙醇脱氢酶越高脸红的越快。这类人很少喝大醉,因大家很少劝他酒,即便喝吐了,休息一下也还能喝。他们体内的乙醛也靠肝脏里的一群氧化酶P450,氧化成二氧化碳和水排出体外。这类人其实不容易伤肝脏。这类人也是醒酒解酒的对象。
由于以上三种代谢方式存在,所以形成,有出汗的,红脸的,白脸的,酒量有高有低的各种现象出现。目前对急性酒精中毒多采用西医治疗,如阿片受体拮抗剂纳洛酮,症状较重的病人,应迅速催吐,中毒后短时间内,用1%碳酸氢钠或0.5%活性炭混悬液或清水反复细微等等。但西药一般都存在或多或少的副作用。本发明针对此缺陷,根据多年临床经验,得到了一种解酒、醒酒、护肝的中药组合物,关于本发明目前还未见报道。
发明内容
本发明的目的是针对现有技术的不足,提供一种解酒、醒酒、护肝的中药组合物及其应用。
为实现上述目的,本发明采取的技术方案是:
第一方面,本发明提供了一种解酒、醒酒、护肝的中药组合物及其应用,所述中药组合物由以下重量份的原料药组成:黄芩6-18份、黄连4-15份、黄柏4-15份、山栀子4-15份、白茯苓9-15份、猪苓9-15份、泽泻12-18份、白术9-15份,桂枝6-12份。
优选地,所述中药组合物由以下重量份的原料药组成:黄芩6-12份、黄连4-10份、黄柏4-10份、山栀子4-10份、白茯苓9-12份、猪苓9-12份、泽泻12-15份、白术9-12份,桂枝6-10份。
优选地,所述中药组合物由以下重量份的原料药组成:黄芩6份、黄连4份、黄柏4份、山栀子4份、白茯苓9份、猪苓9份、泽泻12份、白术9份,桂枝6份。
进一步地,所述中药组合物按照中药常规制备方法制备成临床上可接受的药物制剂。
优选地,所述药物制剂为颗粒剂、散剂、胶囊剂、片剂或口服液。
第二方面,本发明提供了如上所述的中药组合物在制备解酒、醒酒、护肝的药物中的应用。
进一步地,本发明提供了如上所述的中药组合物在制备缓解醉酒后红脸、快速心跳的药物中的应用。
进一步地,本发明提供了如上所述的中药组合物在制备降低血压、血脂的药物中的应用。
第三方面,本发明提供了一种解酒、醒酒、护肝的药物,所述的药物由上所述的中药组合物加水煎煮制成。
优选地,所述的药物制备方法如下:
(1)按照所述重量份配比分别取各原料药:黄芩、黄连、黄柏、山栀子,加水煎煮0.5-1.5小时;
(2)加入白茯苓、猪苓、泽泻,煎煮20-40分钟;
(3)最后加入白术、桂枝,大火烧开,小火煎煮15分钟;
(4)沥出汁水,沉淀取清液,装瓶备用;
(5)整个制备过程,只需煎一次即可。
方解:
酒为肥甘厚味之品,容易酿湿化热,酒后酒精充斥三焦所致。治疗以泻火解毒、化气利尿为原则。方中黄连清泻心火,兼泻中焦之火,为君药;黄芩泻上焦之火,为臣药;黄柏泻下焦之火;栀子泻三焦之火,导热下行,配合茯苓、猪苓、泽泻引邪热从小便而出。四者为佐药。桂枝通阳化气,白术培土制水、输布津液,发挥佐助小便自利的作用,可除体内酒精,二者为使药。其中黄芩、黄连、黄柏配伍清泻三焦火毒,栀子与茯苓、猪苓、泽泻、白术、桂枝引邪从小便而出,各味药材协同奏效,可减缓喝酒后的红脸及快速心跳,加速酒精在体内代谢,通过小便排泄,实现解酒、醒酒、护肝的功效。
本发明优点在于:
1、优选各原料药及其之间的配比,中药组合物配伍符合中医“君臣佐使”的理论,配伍有序,诸药合用,具有减缓喝酒后的红脸及快速心跳,加速酒精在体内代谢,通过小便排泄,实现解酒、醒酒、护肝的功效,疗效佳。
2、方中药味数目少,原材料丰富,制备工艺简单,成本低。
具体实施方式
下面结合具体实施方式,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。此外应理解,在阅读了本发明记载的内容之后,本领域技术人员可以对本发明作各种改动或修改,这些等价形式同样落于本申请所附权利要求书所限定的范围。
实施例1中药组合物(一)
黄芩6份、黄连4份、黄柏4份、山栀子4份、白茯苓9份、猪苓9份、泽泻12份、白术9份、桂枝6份。
实施例2中药组合物(二)
黄芩18份、黄连15份、黄柏15份、山栀子15份、白茯苓15份、猪苓15份、泽泻18份、白术15份,桂枝12份。
实施例3中药组合物(三)
黄芩6份、黄连15份、黄柏4份、山栀子15份、白茯苓9份、猪苓15份、泽泻12份、白术15份,桂枝6份。
实施例4中药组合物(四)
黄芩18份、黄连4份、黄柏15份、山栀子4份、白茯苓15份、猪苓9份、泽泻18份、白术9份,桂枝12份。
实施例5中药组合物(五)
黄芩12份、黄连10份、黄柏10份、山栀子10份、白茯苓12份、猪苓12份、泽泻15份、白术12份,桂枝10份。
实施例6中药组合物(六)
黄芩6份、黄连10份、黄柏4份、山栀子10份、白茯苓9份、猪苓12份、泽泻12份、白术12份,桂枝6份。
实施例7中药组合物(七)
黄芩12份、黄连4份、黄柏10份、山栀子4份、白茯苓12份、猪苓9份、泽泻15份、白术9份,桂枝10份。
实施例8中药组合物(八)
黄芩6份、黄连4份、黄柏4份、山栀子4份、白茯苓9份、猪苓12份、泽泻15份、白术12份,桂枝10份。
实施例9汤剂
制备方法:
(1)分别按照实施例1-8任一所述重量份配比分别取各原料药:黄芩、黄连、黄柏、山栀子,加水煎煮0.5-1.5小时;
(2)加入白茯苓、猪苓、泽泻,煎煮20-40分钟;
(3)最后加入白术、桂枝,大火烧开,小火煎煮15分钟;
(4)沥出汁水,沉淀取清液,装瓶备用;
(5)整个制备过程,只需煎一次即可。
实施例10颗粒剂
制备方法:
(1)分别按照实施例1-8任一所述重量份配比分别取各原料药:黄芩、黄连、黄柏、山栀子,加水煎煮0.5-1.5小时;
(2)加入白茯苓、猪苓、泽泻,煎煮20-40分钟;
(3)最后加入白术、桂枝,大火烧开,小火煎煮15分钟;
(4)滤过,滤液浓缩,待冷却至室温;上清液浓缩,加水,搅拌,静置,取上清液浓缩成清膏;
(5)取清膏制成颗粒;
(6)整个制备过程,只需煎一次即可。
实施例11片剂/胶囊剂
制备方法:
(1)分别按照实施例1-8任一所述重量份配比分别取各原料药:黄芩、黄连、黄柏、山栀子,加水煎煮0.5-1.5小时;
(2)加入白茯苓、猪苓、泽泻,煎煮20-40分钟;
(3)最后加入白术、桂枝,大火烧开,小火煎煮15分钟;
(4)滤过,滤液浓缩,待冷却至室温;
(5)取上清液,浓缩至稠浸膏;
(6)加入制药辅料,真空干燥,粉碎制粒,压制成片剂或填充装胶囊;
(7)整个制备过程,只需煎一次即可。
实施例12解酒醉动物药效实验
1实验动物
昆明种小白鼠60只,体重20±2g,雌雄各半。随机分为六组(模型组、阳性对照组、实验组、对比例一组、对比例二组、对比例三组),每组10只,测试前禁食12小时,试验时小鼠以40度酒0.37mL/20g鼠重的剂量给酒,20min后各组分别灌胃给药,给药量均为0.4人体摄入量的60倍。
2药物
模型组:生理盐水;
阳性对照组:海王金樽;
实验组:实施例1组方;
对比例一组:中药组合物:黄芩5份、黄连18份、黄柏3份、山栀子16份、白茯苓8份、猪苓8份、泽泻10份、白术16份,桂枝15份;
对比例二组:中药组合物:黄芩6份、黄连15份、黄柏4份、山栀子15份。
对比例三组:中药组合物:白茯苓9份、猪苓15份、泽泻12份、白术15份,桂枝6份。
3检测指标
3.1实验结束后分别评价各组小鼠酒后醉倒率及耐受时间和醉睡时间:给酒后开始计时,分别记录小鼠醉倒数及其翻正反射消失时间和恢复时间,计算小鼠酒后醉倒率及其耐受时间和醉睡时间。
3.2评价慢性酒精中毒小鼠酒精性肝损伤情况:经过连续28天的给药给酒实验后,每组待试小鼠禁食12h,次日解剖小鼠,观察内脏器官病变情况,取肝脏进行肝匀浆后测定LPO含量,制成肝切片进行电镜观察肝组织细胞变性情况。
4结果
4.1各组解酒效果
醉倒率(%) | 耐受时间(min) | 醉睡时间(min) | |
模型组 | 100% | 25.30±10.30 | 362.36±96.36 |
阳性对照组 | 50% | 35.42±11.20* | 298.21±48.25* |
实验组 | 0 | 未醉 | 未醉 |
对比例一组 | 10% | 62.36±12.45* | 185.36±20.37* |
对比例二组 | 30% | 56.53±16.36* | 196.14±49.64* |
对比例三组 | 30% | 55.38±15.59* | 192.45±45.78* |
与模型组比较*p<0.05。
以上结果表明实验组小鼠未出现醉倒现象,有效率明显优于其他各组。
4.2各组慢性酒精中毒小鼠酒精性肝损伤结果
结果表明各组小鼠肝匀浆LPO值均显著升高,但其胆囊、胰、肝出现肿大现象且腹下脂肪层肥厚堆积疗效从优到劣依次为:实验组、对比例一组、对比二组(对比例三组)、阳性对照组,其中阳性对照组小鼠在连续给药28天后肉眼可见其胆囊、胰、肝出现肿大现象且腹下脂肪层肥厚堆积严重,肝匀浆的LPO值明大大升高。(此处不再讨论模型组,因为长期的醉酒状态模型组小鼠基本上已经全部死亡)。
实施例13防酒醉动物药效实验
1方法
设计方法同实施例12,区别在于:改成先给药,20min后再给酒,给酒后即开始计时。分别(1)评价急性酒精中毒小鼠酒后醉倒率及其耐受时间、醉睡时间;(2)慢性酒精中毒小鼠酒精性肝损伤情况。
2结果
2.1各组防醉效果
醉倒率(%) | 耐受时间(min) | 醉睡时间(min) | |
模型组 | 100% | 26.36±10.28 | 364.55±92.18 |
阳性对照组 | 60% | 36.15±12.03* | 298.99±46.14* |
实验组 | 10% | 78.34±9.01* | 160.01±10.02* |
对比例一组 | 20% | 63.25±13.64* | 186.99±21.55* |
对比例二组 | 30% | 55.59±15.32* | 195.04±42.61* |
对比例三组 | 30% | 55.69±15.98* | 191.54±40.97* |
与模型组比较*p<0.05。
2.2各组慢性酒精中毒小鼠酒精性肝损伤结果
结果表明各组小鼠肝匀浆LPO值均显著升高,但其胆囊、胰、肝出现肿大现象且腹下脂肪层肥厚堆积疗效从优到劣依次为:实验组、对比例一组、对比二组(对比例三组)、阳性对照组,其中阳性对照组小鼠在连续给药28天后肉眼可见其胆囊、胰、肝出现肿大现象且腹下脂肪层肥厚堆积严重,肝匀浆的LPO值明大大升高。(此处不再讨论模型组,因为长期的醉酒状态模型组小鼠基本上已经全部死亡)。
实施例14临床试验
一、治疗醉酒
120例患者均取自复旦大学附属金山医院医院中医门诊和急症病人,时间集中在2019年6月~2020年6月,其中男92例,女28例,年龄在18-50岁,病程最短酒后2小时,最长酒后8小时。诊断为醉酒,患者主要表现为酒后脸红、快速心跳、头晕、恶心呕吐、口渴欲饮、脘腹胀闷、烦热躁动等。所有患者服用本发明实施例1所述的中药组合物制成的颗粒剂。
结果发现大部分患者45分钟后酒后脸红、快速心跳、头晕、恶心呕吐、口渴欲饮、脘腹胀闷、烦热躁动等症状得到明显改善,1.5小时后上述症状基本消失,总有效率为100%。
二、预防醉酒
120人应试,饮酒前30~60分钟服用本发明实施例1所制备的颗粒剂,饮酒量为通常状态下增加50~100%,120人保持头脑清醒,有效(其中酒后不口渴100人,36人脸红减轻或不红,26人胃痛胀满症状消失,53人心跳加快显现消失);预防醉酒有效率为100%。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员,在不脱离本发明原理的前提下,还可以做出若干改进和补充,这些改进和补充也应视为本发明的保护范围。
Claims (10)
1.一种解酒、醒酒、护肝的中药组合物及其应用,其特征在于,所述中药组合物由以下重量份的原料药组成:黄芩6-18份、黄连4-15份、黄柏4-15份、山栀子4-15份、白茯苓9-15份、猪苓9-15份、泽泻12-18份、白术9-15份,桂枝6-12份。
2.根据权利要求1所述的中药组合物,其特征在于,所述中药组合物由以下重量份的原料药组成:黄芩6-12份、黄连4-10份、黄柏4-10份、山栀子4-10份、白茯苓9-12份、猪苓9-12份、泽泻12-15份、白术9-12份,桂枝6-10份。
3.根据权利要求1所述的中药组合物,其特征在于,所述中药组合物由以下重量份的原料药组成:黄芩6份、黄连4份、黄柏4份、山栀子4份、白茯苓9份、猪苓9份、泽泻12份、白术9份,桂枝6份。
4.根据权利要求1-3任一所述中药组合物,其特征在于,按照中药常规制备方法制备成临床上可接受的药物制剂。
5.根据权利要求4所述的中药组合物,其特征在于,所述药物制剂为颗粒剂、散剂、胶囊剂、片剂或口服液。
6.权利要求1-3任一所述的中药组合物在制备解酒、醒酒、护肝的药物中的应用。
7.权利要求1-3任一所述的中药组合物在制备缓解醉酒后红脸、快速心跳的药物中的应用。
8.权利要求1-3任一所述的中药组合物在制备降低血压、血脂的药物中的应用。
9.一种解酒、醒酒、护肝的药物,其特征在于,所述的药物由权利要求1所述的中药组合物加水煎煮制成。
10.根据权利要求9所述的药物,其特征在于,所述的药物制备方法如下:
(1)按照所述重量份配比分别取各原料药:黄芩、黄连、黄柏、山栀子,加水煎煮0.5-1.5小时;
(2)加入白茯苓、猪苓、泽泻,煎煮20-40分钟;
(3)最后加入白术、桂枝,大火烧开,小火煎煮15分钟;
(4)沥出汁水,沉淀取清液,装瓶备用;
(5)整个制备过程,只需煎一次即可。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011509077.3A CN112546135A (zh) | 2020-12-18 | 2020-12-18 | 一种解酒、醒酒、护肝的中药组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011509077.3A CN112546135A (zh) | 2020-12-18 | 2020-12-18 | 一种解酒、醒酒、护肝的中药组合物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112546135A true CN112546135A (zh) | 2021-03-26 |
Family
ID=75031897
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011509077.3A Pending CN112546135A (zh) | 2020-12-18 | 2020-12-18 | 一种解酒、醒酒、护肝的中药组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112546135A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115737777A (zh) * | 2022-12-19 | 2023-03-07 | 河南中医药大学 | 一种复方解酒中药组合物及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103932173A (zh) * | 2014-03-25 | 2014-07-23 | 姜利 | 一种解酒护肝的组合物 |
-
2020
- 2020-12-18 CN CN202011509077.3A patent/CN112546135A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103932173A (zh) * | 2014-03-25 | 2014-07-23 | 姜利 | 一种解酒护肝的组合物 |
Non-Patent Citations (5)
Title |
---|
何国梁: "《中国中医药出版社》", 30 June 1996, 广东科技出版社 * |
叶森: "《仲景方药现代研究》", 31 October 1997, 中国中医药出版社 * |
根本幸夫: "《我的第一本实用中医对症图典》", 31 March 2012, 天津科学技术出版社 * |
程国彭: "《医学心》", 31 January 2019, 中国中医药出版社 * |
黄煌: "《黄煌经方使用手册 第3版》", 30 April 2018, 中国中医药出版社 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115737777A (zh) * | 2022-12-19 | 2023-03-07 | 河南中医药大学 | 一种复方解酒中药组合物及其制备方法 |
CN115737777B (zh) * | 2022-12-19 | 2023-12-05 | 河南中医药大学 | 一种复方解酒中药组合物及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7234931B2 (en) | Functional food composition having effects of relieving alcohol-induced hangover symptoms and improving liver function | |
CN103656286B (zh) | 缓解酒后不适及降低酒精性肝损伤的组合物及应用 | |
CN101632769B (zh) | 一种调节血糖的中药组合物及其制备方法 | |
CN110604800A (zh) | 一种戒酒解酒护肝植物饮品及制备方法 | |
CN105287899A (zh) | 一种中药解酒茶及其生产工艺 | |
CN105362384B (zh) | 一种解酒醒酒的中药组合物及其应用 | |
CN104208581A (zh) | 一种预防酒精肝的五味子保健口服液及其制备方法 | |
CN107468747A (zh) | 一种有利于抗癌、防癌的人参组合物及其制备方法 | |
CN101757281B (zh) | 治疗胃肠疾病中药组合物及其制备方法 | |
CN105561006A (zh) | 一种具有解酒功能的食品、保健食品或药物组合物及其制备方法和用途 | |
CN112546135A (zh) | 一种解酒、醒酒、护肝的中药组合物及其应用 | |
CN111135235A (zh) | 一种预防和缓解急性酒精中毒或醉酒的组合物 | |
CN105287780A (zh) | 一种植物饮料及其制备方法 | |
CN105641344A (zh) | 一种用于治疗便秘的药物制剂及其用途和制备方法 | |
CN104274705A (zh) | 解酒护肝咀嚼片及其制备方法 | |
CN108684992A (zh) | 一种能快速醒酒的植物配方的解酒饮料及其制备方法 | |
CN108686126B (zh) | 一种护肝解酒组方及制备与应用 | |
CN103007145B (zh) | 一种治疗小儿轮状病毒肠炎的中药组合物及其制备方法 | |
CN105902897A (zh) | 一种治疗胰腺癌的药物制剂及其用途 | |
CN107183426B (zh) | 一种保肝解酒植物饮料、其制备方法及用途 | |
CN102430008A (zh) | 治疗胃肠疾病中药组合物及其制备方法 | |
CN101433577A (zh) | 一种绿豆解酒剂及其制备方法 | |
CN104352717A (zh) | 一种治疗脾气虚弱型便血的中药制剂及其制备方法 | |
CN116270910B (zh) | 一种清暑补液补电解质抗疲劳组合物及其制备方法 | |
CN115607629B (zh) | 一种具有保肝解酒的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210326 |